Latest Breaking News On - Zeva wainberg - Page 3 : vimarsana.com

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer

HAYWARD, Calif. (BUSINESS WIRE) Jan 16, 2024

University of california los angelesUnited statesHolli kolkeyZeva wainbergExchange commissionArcus biosciences incCorporate communicationsGilead sciencesCalifornia los angelesDassault systSynthetic control armAll pooledHistorical controlArcus biosciencePrivate securities litigation reform actQuarterly report

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in Nature Medicine demonstrating tumor biomarker reduction, with strong T cell responses.

United statesSan franciscoLos angelesZeva wainbergHeather divecchiaChristopher haqqElicio therapeutics incLifesci communicationsHead of researchUcla gi oncology programSecurities exchangeUniversity of californiaNature medicineExecutive vice presidentChief medicalSmall bowel

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHolli kolkeyZeva wainbergExchange commissionArcus biosciences incGilead sciencesCorporate communicationsMedian overall survivalSynthetic control armCancers symposiumCalifornia los angelesDassault systAll pooledHistorical controlArcus biosciencePrivate securities litigation reform act

Arcus Biosciences (RCUS) Reports Data from a Phase 1b Study of Quemliclustat-Based Regimens Showing Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer

Arcus Biosciences (RCUS) Reports Data from a Phase 1b Study of Quemliclustat-Based Regimens Showing Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesZeva wainbergArcus biosciences incGilead sciencesArcus biosciencesCalifornia los angelesDassault systSynthetic control armAll pooledHistorical control

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer

Median Overall Survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chemotherapy alone A.

United statesZeva wainbergGilead sciencesArcus biosciences incExchange commissionArcus biosciencesCalifornia los angelesDassault systSynthetic control armAll pooledHistorical controlArcus biosciencePrivate securities litigation reform actQuarterly report